Keith Regnante - 24 Feb 2026 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Keith Regnante
Issuer symbol: KROS
Transactions as of: 24 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 26 Feb 2026, 16:15:23 UTC
Previous filing: 20 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Regnante Keith	CHIEF FINANCIAL OFFICER	C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON	/s/ Keith Regnante	26 Feb 2026	0001682068

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KROS	Employee Stock Option (Right to Buy)	Award	$0	+60,000		$0.000000	60,000	24 Feb 2026	Common Stock	60,000	$15.52	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.